Drug Trial Radar · NCT03347396
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)
Last checked: Nov 20, 2026Latest source record: Oct 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Mar 5, 2018
Primary completion
Oct 5, 2021
Study completion Oct 5, 2021
Sponsor
- Lead sponsor
- Bioverativ, a Sanofi companySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (\>=) 2 grams per deciliter (g/dL) increase in hemoglobin (Hgb) levels or increased Hgb to \>= 12 g/dL and obviated the need for blood transfusion during treatment in participants with primary cold agglutinin disease (CAD) who had a recent history of blood transfusion. The purpose of Part B was to evaluate the long-term safety and tolerability of sutimlimab in participants with CAD.
Conditions
- Agglutinin Disease, Cold
Interventions
BIVV009Drug
Sutimlimab was administered as intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants With Response to TreatmentTime frame: From Week 5 through Week 26
- Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Time frame: Part B, 6.5 g cohort: From first dose (Week 27) up to 143 weeks of treatment + 9 weeks of follow-up (i.e., up to Week 179); Part B, 7.5 g cohort: From first dose (Week 27) up to 149 weeks of treatment + 9 weeks of follow-up (i.e., up to Week 185)
Locations
49 sites in 14 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates PC
Tucson, Arizona
USC/Keck School of Medicine
Los Angeles, California
The Oncology Institute of Hope and Innovation
Whittier, California
Georgetown University Medical Center
Georgetown, District of Columbia
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Montefiore Medical Center
New York, New York
New York Medical College at Westchester Medical Center
Valhalla, New York
East Carolina University
Greenville, North Carolina
Cleveland Clinic
Cleveland, Ohio
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
UW Hospitals and Clinics
Madison, Wisconsin
USC Health Clinics
Buderim, Queensland, Australia
Ballarat Oncology & Haematology
Ballarat, Victoria, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Medical University of Vienna
Vienna, Austria
ZNA Stuivenberg
Antwerp, Belgium
Centre Hospitalier Jolimont
La Louvière, Belgium
University Hospitals Leuven
Leuven, Belgium
University of Alberta
Edmonton, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
McGill University Health Center
Montreal, Quebec, Canada
CHU de Caen
Caen, France
Centre Hospitalier Henri Mondor
Créteil, France
Centre Hospitalier Lyon Sud
Lyon, France
Gemeinschaftspraxis Hämatologie-Onkologie
Dresden, Germany
Universitätsklinikum Essen
Essen, Germany
Univ Ulm, Inst Klin. Transfusions. Immungen
Ulm, Germany
Hadassah Medical Center
Jerusalem, Israel
Laniado Hospital
Netanya, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
A. O. Spedali Civili di Brescia
Brescia, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
U.O.C. Ematologia- Policlinico "A. Gemelli"
Rome, Italy
U.O.C. Ematologia Ospedale San Bortolo
Vicenza, Italy
Tokai University Hospital
Isehara, Kanagawa, Japan
Saitama Medical University Hospital
Iruma-gun, Saitama, Japan
Juntendo University Nerima Hospital
Tokyo, Tokyo-To, Japan
Academisch Medisch Centrum
Amsterdam, Netherlands
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.